每经AI快讯，港股部分医药股午后拉升。截至发稿，康希诺生物(06185.HK)涨10.13%，报40.86港元； 君实生物(01877.HK)涨5.19%，报23.92港元；复旦张江(01349.HK)涨4.11%，报3.29港元。 ...

消息面上，1月26日，印度出现尼帕病毒疫情相关话题冲上热搜，引发关注。据新华社报道，印度出现 尼帕病毒疫情。邻近国家正严阵以待。感染者集中在印度西孟加拉邦。截至本文发稿，确诊感染病例已 达5例，至少一人病情危重，另有近百人被要求居家隔离。 公开资料显示，尼帕是人畜共患的RNA病毒，主要由果蝠和猪携带，死亡率在40%至75%之间，潜伏期 一般为4天至14天。目前尚无专门的疫苗和有效疗法，治疗侧重于控制症状和提供支持性护理。 智通财经APP获悉，部分医药股午后拉升。截至发稿，康希诺生物(06185)涨10.13%，报40.86港元；君 实生物(01877)涨5.19%，报23.92港元；复旦张江(01349)涨4.11%，报3.29港元。 ...

Core Viewpoint - The report highlights the current premium rates of AH shares, with Northeast Electric, Zhejiang Shibao, and Junda Co. leading in premium rates, while CATL, Hengrui Medicine, and China Merchants Bank are at the bottom of the list [1][2]. Premium Rate Rankings - Northeast Electric (00042) has a premium rate of 815.25%, followed by Zhejiang Shibao (01057) at 378.67% and Junda Co. (02865) at 342.63% [2]. - The lowest premium rates are recorded for CATL (03750) at -13.79%, Hengrui Medicine (01276) at -2.52%, and China Merchants Bank (03968) at -2.22% [1][2]. Deviation Values - Junda Co. (02865) has the highest deviation value at 104.89%, followed by Goldwind Technology (02208) at 23.62% and Guanghetong (00638) at 20.17% [1][2]. - The lowest deviation values are for Northeast Electric (00042) at -35.64%, Chenming Paper (01812) at -16.87%, and China Life (02628) at -15.34% [1][4]. Additional Insights - The report includes a detailed table of the top ten and bottom ten AH stocks based on premium rates and deviation values, providing a comprehensive overview of the current market situation [2][3][4].

Core Viewpoint - Fudan Zhangjiang (688505.SH) announced that Mr. Yang Zongmeng has implemented a share reduction plan, reducing his holdings in the company by 10.3657 million shares, which accounts for 1.00% of the company's total share capital [1] Group 1 - The share reduction took place between November 26, 2025, and January 12, 2026 [1] - The reduction was executed through centralized bidding transactions [1]

Group 1 - The major shareholder, Yang Zongmeng, held 64,009,773 shares, representing 6.18% of the total share capital before the reduction plan [2] - Yang Zongmeng planned to reduce his holdings by up to 10,365,721 shares, which is no more than 1.00% of the total share capital, due to personal funding needs [3] - The reduction was successfully completed between November 26, 2025, and January 12, 2026, with a total of 10,365,721 shares sold, matching the planned reduction [4]

Shareholder Reduction - New China Group's shareholder, New Work Group, plans to reduce its stake by no more than 3% [1] - Shuyuan Pingmin's shareholder, Alibaba Health, intends to reduce its stake by no more than 2% [1] - Zhejiang Yongqiang's shareholder, Xie Jianqiang, plans to reduce his stake by no more than 1.13% [1] - Xiangyu Medical's shareholder, Anyang Qixu, intends to reduce his stake by no more than 3% [1] - Zhangyue Technology's shareholder, Quantum Leap, plans to reduce its stake by no more than 1% [1] - Fudan Zhangjiang's shareholder, Yang Zongmeng, has reduced 10.3657 million shares [1] - Saiwei Times' shareholder, Zhongteng Investment, has reduced 12.1037 million shares [1] - Aokang International's shareholder, Xiang Jinyu, has cumulatively reduced 1.21% of the company's shares [1] - Fute Technology's shareholder, Changjiang Weilai Industrial Fund, has cumulatively reduced 1.6492% of the shares [1] - New Giant's shareholder, Suzhou Houqi, has cumulatively reduced 1.4997% of the shares [1] - Baolingbao's shareholder, De Pufutong, has cumulatively reduced 1.10689% of the shares [1] - Hongqiang's actual controller, Liu Lianjun, plans to reduce his stake by no more than 1% [1] - Yashiguangdian's shareholder, Bian Ruiqun, has cumulatively reduced 1.0695% of the shares [1] Other Financial Issues - Ruimao Tong has reported overdue debts amounting to approximately 856 million yuan [1] - *ST Dongjing is under investigation by the Securities Regulatory Commission due to independent director Fu Baoshan's suspected insider trading [1]

Core Viewpoint - Fudan Zhangjiang (01349) announced that Mr. Yang Zongmeng has implemented a share reduction plan, reducing his holdings in the company [1] Summary by Relevant Sections - Share Reduction Details - Mr. Yang Zongmeng reduced his shareholding by a total of 10,365,721 shares from November 26, 2025, to January 12, 2026, which represents 1.00% of the company's total share capital [1] - The total amount of the reduction is approximately 91.083 million yuan [1]

Core Viewpoint - Fudan Zhangjiang (01349) has announced a share reduction plan implemented by Mr. Yang Zongmeng, involving a total reduction of 10,365,721 shares, which represents 1.00% of the company's total share capital, with a total amount of approximately 91.083 million yuan [1] Group 1 - The share reduction occurred between November 26, 2025, and January 12, 2026, through centralized bidding transactions [1] - The total number of shares reduced is 10,365,721 [1] - The total amount from the share reduction is approximately 91.083 million yuan [1]

海外監管公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內 容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公告乃上海復旦張江生物醫藥股份有限公司（「本公司」）根據香港聯合交易所有 限公司證券上市規則第 13.10(B)條刊發。 茲載列本公司於上海證券交易所網站刊發的《上海復旦張江生物醫藥股份有限公司關 於持股 5%以上股東減持股份結果公告》，僅供參閱。該文件及其披露內容乃根據中國 法律法規及境內相關監管要求而編制及刊發。 承董事會命 趙大君 主 席 於本公告刊發日期，董事會包括以下人士： 中國·上海 二零二六年一月十三日 *僅供識別 趙大君先生（執行董事） 薛 燕女士（執行董事） 沈 波先生（非執行董事） 余曉陽女士（非執行董事） 王宏廣先生（獨立非執行董事） 林兆榮先生（獨立非執行董事） 徐培龍先生（獨立非執行董事） 曲亞楠女士（職工董事） 本次减持计划实施前，上海复旦张江生物医药股份有限公司（以下简称"公 司"或"复旦张江"）股东杨宗孟先生持有公司股份 64,009,773 股，占公司总股本 ...

证券代码：688505 证券简称：复旦张江 公告编号：临 2026-002 上海复旦张江生物医药股份有限公司 关于持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，上海复旦张江生物医药股份有限公司（以下简称"公 司"或"复旦张江"）股东杨宗孟先生持有公司股份 64,009,773 股，占公司总股本 的 6.18%。杨宗孟先生所持有的公司股份来源为公司首次公开发行前取得的股份， 该部分股份已于 2023 年 6 月 19 日起全部解除限售并上市流通。 1、2025 年 11 月 5 日，公司于上海证券交易所网站（www.sse.com.cn）披露 了《关于持股 5%以上股东减持股份计划公告》（公告编号：临 2025-038）。因自 身资金需求，杨宗孟先生计划通过集中竞价交易的方式减持公司股份不超过 10,365,721 股，拟减持比例不超过公司总股本的 1.00%。 2、公司于近日收到杨宗孟先生出具的《关于股份减持计划实施 ...